“
“The eastern and southern Africa (ESA) region is considered as a centre of secondary diversity for pigeonpea. Accessions (297) of pigeonpea landraces were collected from major production areas in four countries in the region and evaluated for desirable agronomic traits, particularly resistance to fusarium wilt and market-preferred

traits. Selected germplasm was utilized in the regional breeding program aimed at genetic enhancement of pigeonpea. Five improved long-duration (LD) cultivars that are highly resistant to fusarium wilt and have large (100-grain weight >15.0 g) grains were developed. Similarly, six early maturing medium-duration (MD) cultivars (averaging 2.5 t/ha) for production in the high latitude areas in the region and three MD cultivars that are able to ratoon, were developed. Seed of pre-released cultivars SB203580 that are preferred by the farmers was distributed widely in the region in order to facilitate adoption. Consequently, the selleck products productivity of pigeonpea and food security in the region improved significantly.”
“Clinics in developing nations often use paper-based records that are hard to manage or are inefficient. Electronic medical records (EMR) systems could help increase

the efficiency and efficacy of these clinics. Even though some EMR systems have been developed for developing countries, they lack customizability. This paper gives some background information about EMR systems: how they are used in developed countries, and how FileMaker, an off-the-shelf database software, could be used to rapidly deploy EMR systems in clinics and hospitals of developing

countries. An existing EMR database developed by Banner Alzheimer’s Institute serves as a proof of concept that FileMaker is a viable EMR solution.”
“Background: Coadministration of 1,4-dihydropyridine calcium channel blockers (DHP-CCBs) with statins (or 3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) is common for patients with hypercholesterolemia and hypertension. To reduce the risk of myopathy, in 2011, the US Food and Drug Administration (FDA) Drug Safety Communication set a new dose limitation for simvastatin, for Chk inhibitor patients taking simvastatin concomitantly with amlodipine. However, there is no such dose limitation for atorvastatin for patients receiving amlodipine. The combination pill formulation of amlodipine/atorvastatin is available on the market. There been no systematic review of the pharmacokinetic drug-drug interaction (DDI) profile of DHP-CCBs with statins, the underlying mechanisms for DDIs of different degree, or the corresponding management of clinical risk. Methods: The relevant literature was identified by performing a PubMed search, covering the period from January 1987 to September 2013.